Latest Tenders From Germany

Completion of Non-exclusive Drug Discounts According to Section 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Cinacalcet (atc Code Who: H05bx01)

Conclusion of Non-Exclusive Discount Agreements in Accordance with §§ 130A Para. 8/130C Para. 1 Sgb V for Drugs with the Active Ingredient Certolizumab Pegol (L04ab05) as Part of an Open House Model.

Completion of Non-exclusive Drug Discounts According to § 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Tamsulosin/dutastasteride (atc Code Who: G04ca52)

Drug Discount Contracts According to § 130A Paragraph 8 Sgb V in the Context of Open House Procedures

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Substance Ranolazine (Atc Code Who: C01eb18)

Conclusion of Non-Exclusive Drug Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Open House Model for the Active Ingredient Raltegravir (Atc Code Who: J05aj01)

Open House Biologics Rebate Contracts 2023-04 - Triptorelin Embonat

Completion of Non-exclusive Drug Discounts According to § 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Ranolazine (atc Code Who: C01eb18)

Completion of Non-exclusive Drug Discounts According to Section 130a (8) Sgb V by Means of a So-called Open-house Model to the Active Ingredient Raltegravir (atc Code Who: J05aj01)

Conclusion of Non-Exclusive am Discount Agreements According to § 130A Para. 8 Sgb V by Means of a So-Called Oh Model for the Active Ingredient Interferon Beta-1A for Subcutaneous Injection (Atc Code According to Who: L03ab07)